REGγ/PA28γ proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number

Cell Cycle

Volumn 8, Issue 15, 2009, Pages 2399-2407

  Zannini, Laura ^a   Buscemi, Giacomo ^a   Fontanella, Enrico ^a   Lisanti, Sofia ^a   Delia, Domenico ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

APL; Checkpoint; PML nuclear bodies; Proteasome; Sumoylation

Indexed keywords

CHECKPOINT KINASE 2; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; AUTOANTIGEN; KI ANTIGEN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SUMO 1 PROTEIN; SUMO1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL COUNT; CELL NUCLEUS INCLUSION BODY; CELL STRUCTURE; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; CELL NUCLEUS; ENZYMOLOGY; FIBROBLAST; METABOLISM; TUMOR CELL LINE; ULTRASTRUCTURE;

AUTOANTIGENS; CELL LINE, TUMOR; CELL NUCLEUS; FIBROBLASTS; HUMANS; INTRANUCLEAR INCLUSION BODIES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; SUMO-1 PROTEIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 68449095278     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.15.9084     Document Type: Article

References (40)

1. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005; 15:27-33. (Pubitemid 40094678)
2. Hill CP, Masters EI, Whitby FG. The 11S regulators of 20S proteasome activity. Curr Top Microbiol Immunol 2002; 268:73-89.
3. Murata S, Kawahara H, Tohma S, Yamamoto K, Kasahara M, Nabeshima Y, et al. Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem 1999; 274:38211-38215 (Pubitemid 30026896)
4. Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol 2004; 172:3948-3954 (Pubitemid 38337983)
5. Li X, Lonard DM, Jung SJ, Malovannaya A, Feng Q, Qin J, et al. The SRC-3/ AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 2006; 124:381-392 (Pubitemid 43121985)
6. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, et al. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007; 104:1661-1666 (Pubitemid 46214647)
7. Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, et al. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 2006; 116:2972-2984 (Pubitemid 44684482)
8. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell cycle inhibitors by the REGγ proteasome. Mol Cell 2007; 26:843-852 (Pubitemid 46921008)
9. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGγ-proteasome pathway. Mol Cell 2007; 26:831-842 (Pubitemid 46921009)
10. Zhang Z, Zhang R. Proteasome activator PA28gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J 2008; 27:852-864
11. Zannini L, Lecis D, Buscemi G, Carlessi L, Gasparini P, Fontanella E, et al. REGgamma proteasome activator is involved in the maintenance of chromosomal stability. Cell Cycle 2008; 7:504-512
12. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001; 20:7216-7222
13. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007; 8:1006-1016 (Pubitemid 350174636)
14. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002; 4:865-870 (Pubitemid 35331361)
15. Dellaire G, Bazett-Jones DP. Beyond repair foci: subnuclear domains and the cellular response to DNA damage. Cell Cycle 2007; 6:1864-1872 (Pubitemid 47327904)
16. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 2007; 7:925-936
17. Buscemi G, Zannini L, Fontanella E, Lecis D, Lisanti S, Delia D. The shelterin protein TRF2 inhibits Chk2 activity at telomeres in the absence of DNA damage. Curr Biol 2009; 19:874-879
18. Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG, et al. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2 and ATR. J Cell Biol 2006; 175:55-66. (Pubitemid 44537198)
19. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193:1361-1371
20. Fabunmi RP, Wigley WC, Thomas PJ, DeMartino GN. Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. J Cell Sci 2001; 114:29-36.
21. LaMorte VJ, Dyck JA, Ochs RL, Evans RM. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci USA 1998; 95:4991-4996 (Pubitemid 28208538)
22. Zhang Z, Clawson A, Realini C, Jensen CC, Knowlton JR, Hill CP, et al. Identification of an activation region in the proteasome activator REGalpha. Proc Natl Acad Sci USA 1998; 95:2807-2811 (Pubitemid 28135810)
23. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10:547-555 (Pubitemid 351627374)
24. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10:538-546 (Pubitemid 351627373)
25. Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 2001; 20:7257-7265 (Pubitemid 33107375)
26. Yang S, Jeong JH, Brown AL, Lee CH, Pandolfi PP, Chung JH, Kim MK. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem 2006; 281:26645-26654 (Pubitemid 44401873)
27. Varadaraj A, Dovey CL, Laredj L, Ferguson B, Alexander CE, Lubben N, et al. Evidence for the receipt of DNA damage stimuli by PML nuclear domains. J Pathol 2007; 211:471-480 (Pubitemid 46332559)
28. Buscemi G, Savio C, Zannini L, Micciche F, Masnada D, Nakanishi M, et al. Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol 2001; 21:5214-5222 (Pubitemid 32656416)
29. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007; 6:935-944 (Pubitemid 46554563)
30. Dellaire G, Ching RW, Dehghani H, Ren Y, Bazett-Jones DP. The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci 2006; 119:1026-1033
31. Eskiw CH, Dellaire G, Mymryk JS, Bazett-Jones DP. Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J Cell Sci 2003; 116:4455-4466 (Pubitemid 37369600)
32. Cioce M, Boulon S, Matera AG, Lamond AI. UV-induced fragmentation of Cajal bodies. J Cell Biol 2006; 175:401-413
33. Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, et al. A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell 2008; 19:1706-1716 (Pubitemid 351805122)
34. Janer A, Martin E, Muriel MP, Latouche M, Fujigasaki H, Ruberg M, et al. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol 2006; 174:65-76. (Pubitemid 43992897)
35. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20:7234-7242 (Pubitemid 33105012)
36. Mikolajczyk J, Drag M, Békés M, Cao JT, Ronai Z, Salvesen GS. Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J Biol Chem 2007; 282:26217-26224 (Pubitemid 47443769)
37. Melchior F, Schergaut M, Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci 2003; 28:612-618 (Pubitemid 38352808)
38. 2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci 2003; 116:513-524
39. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 2004; 26:963-977 (Pubitemid 39273070)
40. Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, Delia D. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 2003; 278:42346-42351 (Pubitemid 37310504)